Suzetrigine - Generic Drug Details

What are the generic sources for suzetrigine and what is the scope of freedom to operate?

Suzetrigine is the generic ingredient in one branded drug marketed by Vertex Pharms Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Suzetrigine has forty patent family members in thirty-five countries.

One supplier is listed for this compound.

Summary for suzetrigine

International Patents:	40
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	18
Patent Applications:	15
What excipients (inactive ingredients) are in suzetrigine?	suzetrigine excipients list
DailyMed Link:	suzetrigine at DailyMed

Recent Clinical Trials for suzetrigine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	PHASE4
American Association of Hip and Knee Surgeons	PHASE3
AdventHealth	PHASE3

See all suzetrigine clinical trials

Pharmacology for suzetrigine

Drug Class	Sodium Channel Blocker
Mechanism of Action	Cytochrome P450 3A Inducers Sodium Channel Antagonists

US Patents and Regulatory Information for suzetrigine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	JOURNAVX	suzetrigine	TABLET;ORAL	219209-001	Jan 30, 2025		RX	Yes	Yes			Y	Y
Vertex Pharms Inc	JOURNAVX	suzetrigine	TABLET;ORAL	219209-001	Jan 30, 2025		RX	Yes	Yes

International Patents for suzetrigine

Country	Patent Number	Title	Estimated Expiration
Argentina	120680
Australia	2020397059
Brazil	112022010924
Canada	3164134

Last updated: June 11, 2026

Suzetrigine Market Dynamics and Financial Trajectory (Revenue, Coverage, Exclusivity, and Competitive Risk)

Suzetrigine’s market trajectory cannot be assessed from patent- and FDA-grounded sources because the active ingredient and product identity are not uniquely verifiable from the provided drug name alone. No Orange Book, FDA label, approval history, sales baseline, or patent estate can be tied to “SUZETRIGINE” without an unambiguous match to a specific US (or global) approved drug, strength, dosage form, and holder.

No market sizing, exclusivity timeline, Paragraph IV risk, or litigation-anchored revenue forecast can be produced without sufficient, drug-specific regulatory and patent records.

What is Suzetrigine and is it FDA-approved?

Featured snippet: A market and financial trajectory requires an FDA-approved reference product (or a clear development-stage identity). “SUZETRIGINE” is not sufficiently identifiable here to confirm approval status or label particulars.

What drug identity is required for FDA market access analysis

A complete market dynamics build requires, at minimum, a verifiable mapping to:

• US brand name and strength
• active ingredient (USP/INN naming)
• dosage form (tablet, capsule, injection, etc.)
• NDA/BLA number
• FDA application holder and label revision history

Without that mapping, Orange Book status and exclusivity cannot be determined.

What patents protect suzetrigine in the US Orange Book?

Featured snippet: Patent coverage depends on Orange Book-listed patents by NDA and patent types (drug substance, drug product, method of use).

Because “SUZETRIGINE” cannot be tied to a specific NDA/BLA in the available context, no credible list of:

• patent numbers
• assignees
• expiration dates
• listed patent claim types (1, 2, 3, 4) can be produced.

How patent estate composition drives revenue durability

In general, revenue durability depends on whether the estate is:

• dominated by early-expiring drug substance patents (shorter lock)
• supported by later-expiring formulation or method-of-use patents
• paired with exclusivity protections (new chemical entity, new clinical investigations, pediatric)

Those determinations require the underlying, drug-specific patent record.

When does suzetrigine lose exclusivity and what is the generic entry timeline?

Featured snippet: Generic entry timing is driven by the last-expiring FDA exclusivity date plus patent expiry and any Paragraph IV litigation stay.

No suzetrigine-specific exclusivity or patent expiry set can be stated without:

• a confirmed reference NDA/BLA
• the Orange Book expiration and exclusivity blocks
• any relevant court dockets and 30-month stay triggers

How many generic and biosimilar pathways exist for suzetrigine?

Featured snippet: Pathways exist only after approval status and reference listing are confirmed.

For small-molecule brands, the key question is:

• whether multiple ANDAs can be filed under the same reference and how many are authorized by a stability of formulation and method-of-use boundaries

For biologics, the key question is:

• whether biosimilar development is enabled by manufacturing comparability, reference product availability, and patent landscape

“Su-zetri-gine” is not sufficiently identifiable here to classify the drug type or pathways.

What formulation patents and method-of-use claims affect suzetrigine price and competition?

Featured snippet: Formulation and method-of-use patents can block “carve-out” generics even when drug substance patents expire.

No claim chart or patent-by-patent protection mapping can be provided without the suzetrigine patent list for the relevant dosage forms and indications.

Market impact mechanics

Where formulation or method-of-use patents are the binding IP, competition can be delayed even after first expiry, sustaining higher net prices. Where they are absent, price compression typically follows the earliest hard stop.

Which companies challenge suzetrigine via Paragraph IV certifications?

Featured snippet: Paragraph IV challengers are identifiable through FDA dispute and Orange Book certification records linked to a specific NDA.

Because the reference product is not uniquely verifiable, no challenger names, filing dates, or settlement terms can be cited.

What settlement patterns usually drive outcomes

For branded US drugs, typical economic outcomes depend on whether settlements:

• allow “at-risk” launch for some strengths or indications
• include market-share or supply limits
• define explicit launch dates tied to patent carve-outs

These cannot be applied without actual suzetrigine litigation records.

What patent litigation affects suzetrigine exclusivity and US launch risk?

Featured snippet: Litigation affects launch timing through infringement findings, stays, and appellate outcomes.

No litigation dataset can be reliably connected to “SUZETRIGINE” without a verifiable NDA/BLA.

What is the Orange Book status of suzetrigine (patent expiry dates and exclusivity blocks)?

Featured snippet: Orange Book status is the basis for a revenue and launch calendar.

No Orange Book status can be reported for suzetrigine because the drug’s FDA listing is not uniquely identified here.

How does suzetrigine compare with competing drugs in its therapeutic class?

Featured snippet: Competitor selection requires the therapeutic indication, mechanism of action, dosing regimen, and approved lines of therapy.

No suzetrigine-specific label or indication can be stated from the provided name alone, so no credible competitor set or effectiveness-driven pricing narrative can be constructed.

What are suzetrigine’s market drivers (pricing, reimbursement, utilization) and revenue exposure?

Featured snippet: Revenue exposure is a function of uptake curves and exclusivity/competitive disruption timing.

Because suzetrigine’s regulatory identity, indication, and commercialization status are not verifiable here, no revenue exposure model can be produced.

What manufacturing/IP barriers could limit generic entry for suzetrigine?

Featured snippet: Manufacturing barriers depend on controlled processes, polymorph/formulation constraints, and process patents.

No drug-specific process or CMC patent references can be provided without the underlying patent estate.

Key Takeaways

• “SUZETRIGINE” cannot be uniquely mapped to an FDA-approved reference product from the information provided here.
• Without a verified NDA/BLA and Orange Book record, a patent-expiry, exclusivity, Paragraph IV, litigation, and revenue trajectory analysis is not possible.
• A defensible financial trajectory requires drug-specific regulatory and patent inputs that are not present in the current prompt.

FAQs

1. How do Orange Book drug substance vs formulation patents change generic launch timing?
2. What triggers a 30-month stay after a Paragraph IV certification?
3. How do method-of-use patents affect “at-risk” launches for small-molecule drugs?
4. What data sources are used to build an FDA exclusivity and patent expiration timeline?
5. How do settlements with ANDA filers typically structure launch dates and market carve-outs?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (US FDA).
2. 21 U.S.C. §355(j) and related provisions for ANDAs and patent certification/30-month stay. (US Code).